BCM
CGTX icon

BIOS Capital Management’s Cognition Therapeutics CGTX Stock Holding History

BIOS Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.56M Hold
6,000,000
– – 8.63% 3
2025
Q4 		$8.1M Hold
6,000,000
– – 9.8% 2
2025
Q3 		$8.1M Hold
6,000,000
– – 9.11% 2
2025
Q2 		$1.86M Hold
6,000,000
– – 2.56% 5
2025
Q1 		$2.52M Hold
6,000,000
– – 3.19% 4
2024
Q4 		$4.21M Buy
+6,000,000
New +$2.97M 4.47% 2

Other funds holding CGTX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

BIOS Capital Management's CGTX Position: Q1 2026 in Review

BIOS Capital Management held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 6,000,000 shares worth $4.56M. The position accounts for 8.63% of the portfolio, ranked #3.

BIOS Capital Management first reported a position in CGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.1M in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • BIOS Capital Management held 6,000,000 shares of Cognition Therapeutics worth $4.56M as of Q1 2026.
  • BIOS Capital Management left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up 8.63% of BIOS Capital Management's portfolio in Q1 2026, its #3 holding.
  • BIOS Capital Management first reported a position in Cognition Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BIOS Capital Management's Cognition Therapeutics position peaked at $8.1M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on BIOS Capital Management's 13F filing for Q1 2026, filed 13 May 2026.